Properties
What is it?
NEVANAC Composition: Active substance: Nepafenac; 1 ml of suspension contains 1 mg of Nepafenac; Excipients: Mannitol (E421), Carbomer 974P, Sodium chloride, Tyloxapol, Disodium edetate, Benzalkonium chloride, Sodium hydroxide and/or Hydrochloric acid (for pH adjustment), Purified water. Dosage form. Eye drops, suspension. A homogeneous suspension from pale yellow to pale orange. Pharmacotherapeutic group. Ophthalmic preparations. Non-steroidal anti-inflammatory drugs. Nepafenac. ATC code: S01BC10. Clinical characteristics. Indications: • - Prevention and treatment of post-operative pain and inflammation after surgical removal of cataract. • - Reduction of the risk of post-operative macular edema associated with cataract surgery in patients with diabetes. Contraindications. Individual hypersensitivity to the active substance, any of the excipients, or other non-steroidal anti-inflammatory drugs (NSAIDs). Method of administration and dosage. For the prevention and treatment of post-operative pain and inflammation, instill 1 drop of the preparation into the conjunctival sac of the affected eye(s) 3 times a day, starting from the first day before cataract surgery and up to the 14th day of the post-operative period. An additional drop should be instilled 30-120 minutes before surgery. Treatment may be continued in the post-operative period for up to 3 weeks (21 days), according to doctor's instructions. To reduce the risk of post-operative macular edema associated with cataract surgery in patients with diabetes, the dose is 1 drop of the preparation into the conjunctival sac of the affected eye(s) 3 times a day, starting 1 day before cataract surgery and up to 60 days in the post-operative period. An additional drop must be instilled 30-120 minutes before surgery. Children. The safety and efficacy of Nevanac eye drops in patients under 18 years of age have not been studied, and therefore the use of the preparation in this group of patients is not recommended. Use in patients with impaired liver and kidney function. The use of Nevanac in patients with liver diseases or impaired kidney function has not been studied. Nepafenac is primarily excreted via metabolism, and its systemic effect after topical application is very insignificant. Dose adjustment is not required for such patients. Method of administration. For topical ophthalmic use only. Shake the bottle before use. If more than one topical ophthalmic medicinal product is used, the interval between the administration of the preparations should be at least 5 minutes. The tip of the dropper bottle should not touch the eyes or any other surface to avoid contamination of the dropper tip and the contents of the bottle. After use, it is recommended to close the bottle tightly with the cap. Interaction with other medicinal products and other types of interaction. Concomitant use of topical NSAIDs and topical corticosteroids may complicate wound healing. Concomitant use of Nevanac and medications that increase blood clotting time may increase the risk of bleeding. Interaction with other medicinal products is unlikely.